Biocept Inc. (BIOC)

6.22 -0.26 (-4.012%)

IEX Real-Time Price

July 20, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 6.48

Price Open 6.5

Volume: 234,562

Avg Volume: 881,945

Market Cap: 14.14M

P/E Ratio -0.3

52 Wk Range 3.5-44.547



BIOC Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-06-29
1.72M
185,591
3.69
10.81%

2018-06-15
67.68M
6.09M
5.07
9.00%

2018-05-31
67.68M
5.3M
5.09
7.82%

2018-05-15
67.68M
5.42M
5.33
8.01%




BIOC Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-15
Q1 2018
AMC
-0.07 (1)
-0.11
-0.04

2018-05-10
Q1 2018
N/A
0.00 (0)
0.00
0.00

2018-03-28
Q4 2017
AMC
-0.19 (1)
-0.18
0.01

2018-03-13
Q4 2017
N/A
-0.19 (1)
-0.18
0.01

News

Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record (2018-07-19 09:00 PR Newswire)

SAN DIEGO , July 19, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today issued a reminder…

 


Statistics

Shares Outstanding: 2.27M

Top 15 Institution Percent: 10.00

Price To Sales: 5.06

Price To Book: 1.73

Revenue: 2.39M

Gross Profit: -2465387

Cash: 15.88M

Debt: 4.43M

Return On Assets: -144.04

Return On Equity: -248.73

Profit Margin: N/A

Price History

Beta: 2.15

50-day Moving Avg: 6.36

200-day Moving Avg: 14.58

YTD Change: -70.38

5-day Change: -11.02

1-month Change: -22.38

3-month Change: -17.07

6-month Change: -70.27

1-year Change: -85.99

Revenue Per Share: 1.00

Revenue Per Employee: 25162.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Biocept Inc.

Exchange: NASDAQ Capital Market

Industry: Medical Diagnostics & Research

Sector: Healthcare

Website: http://www.biocept.com

Biocept Inc is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample.